Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in CD30-positive systemic mastocytosis
NCT01807598Phase 2Completed
- Start
- Sep 2013
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin in systemic mastocytosis (SM) and mast cell leukemia (MCL). Primary endpoint: Overall Response Rate at 1 year. Started Sep 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
systemic mastocytosis (SM)mast cell leukemia (MCL)
Beyond the preview
Go deeper on NCT01807598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01807598.